Safety profile of the 9-valent HPV vaccine

A combined analysis of 7 phase III clinical trials

Edson D. Moreira, Stan L. Block, Daron Gale Ferris, Anna R. Giuliano, Ole Erik Iversen, Elmar A. Joura, Pope Kosalaraksa, Andrea Schilling, Pierre Van Damme, Jacob Bornstein, F. Xavier Bosch, Sophie Pils, Jack Cuzick, Suzanne M. Garland, Warner Huh, Susanne K. Kjaer, Hong Qi, Donna Hyatt, Jason Martin, Erin Moeller & 3 others Michael Ritter, Martine Baudin, Alain Luxembourg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at entry), 9 to 26 years of age. METHODS: Vaccination was administered as a 3-dose regimen at day 1, and months 2 and 6. More than 15 000 subjects received ≥1 dose of 9vHPV vaccine. In 2 of the studies, >7000 control subjects received ≥1 dose of quadrivalent HPV (qHPV) vaccine. Serious and nonserious adverse events (AEs) and new medical conditions were recorded throughout the study. Subjects testing positive for pregnancy at day 1 were not vaccinated; those who became pregnant after day 1 were discontinued from further vaccination until resolution of the pregnancy. Pregnancies detected after study start (n = 2950) were followed to outcome. RESULTS: The most common AEs (≥5%) experienced by 9vHPV vaccine recipients were injection-site AEs (pain, swelling, erythema) and vaccine-related systemic AEs (headache, pyrexia). Injection-site AEs were more common in 9vHPV vaccine than qHPV vaccine recipients; most were mild-to-moderate in intensity. Discontinuations and vaccine-related serious AEs were rare (0.1% and <0.1%, respectively). Seven deaths were reported; none were considered vaccine related. The proportions of pregnancies with adverse outcome were within ranges reported in the general population. CONCLUSIONS: The 9vHPV vaccine was generally well tolerated in subjects aged 9 to 26 years with an AE profile similar to that of the qHPV vaccine; injection-site AEs were more common with 9vHPV vaccine. Its additional coverage and safety profile support widespread 9vHPV vaccination.

Original languageEnglish (US)
Article numbere20154387
JournalPediatrics
Volume138
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Papillomavirus Vaccines
Phase III Clinical Trials
Safety
Pregnancy
Vaccination
Vaccines
Injections
Erythema
Headache
Fever
Pain

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Moreira, E. D., Block, S. L., Ferris, D. G., Giuliano, A. R., Iversen, O. E., Joura, E. A., ... Luxembourg, A. (2016). Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics, 138(2), [e20154387]. https://doi.org/10.1542/peds.2015-4387

Safety profile of the 9-valent HPV vaccine : A combined analysis of 7 phase III clinical trials. / Moreira, Edson D.; Block, Stan L.; Ferris, Daron Gale; Giuliano, Anna R.; Iversen, Ole Erik; Joura, Elmar A.; Kosalaraksa, Pope; Schilling, Andrea; Van Damme, Pierre; Bornstein, Jacob; Bosch, F. Xavier; Pils, Sophie; Cuzick, Jack; Garland, Suzanne M.; Huh, Warner; Kjaer, Susanne K.; Qi, Hong; Hyatt, Donna; Martin, Jason; Moeller, Erin; Ritter, Michael; Baudin, Martine; Luxembourg, Alain.

In: Pediatrics, Vol. 138, No. 2, e20154387, 01.08.2016.

Research output: Contribution to journalArticle

Moreira, ED, Block, SL, Ferris, DG, Giuliano, AR, Iversen, OE, Joura, EA, Kosalaraksa, P, Schilling, A, Van Damme, P, Bornstein, J, Bosch, FX, Pils, S, Cuzick, J, Garland, SM, Huh, W, Kjaer, SK, Qi, H, Hyatt, D, Martin, J, Moeller, E, Ritter, M, Baudin, M & Luxembourg, A 2016, 'Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials', Pediatrics, vol. 138, no. 2, e20154387. https://doi.org/10.1542/peds.2015-4387
Moreira, Edson D. ; Block, Stan L. ; Ferris, Daron Gale ; Giuliano, Anna R. ; Iversen, Ole Erik ; Joura, Elmar A. ; Kosalaraksa, Pope ; Schilling, Andrea ; Van Damme, Pierre ; Bornstein, Jacob ; Bosch, F. Xavier ; Pils, Sophie ; Cuzick, Jack ; Garland, Suzanne M. ; Huh, Warner ; Kjaer, Susanne K. ; Qi, Hong ; Hyatt, Donna ; Martin, Jason ; Moeller, Erin ; Ritter, Michael ; Baudin, Martine ; Luxembourg, Alain. / Safety profile of the 9-valent HPV vaccine : A combined analysis of 7 phase III clinical trials. In: Pediatrics. 2016 ; Vol. 138, No. 2.
@article{0d8754bd19fe4f0883dd8e9e891306d9,
title = "Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials",
abstract = "OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at entry), 9 to 26 years of age. METHODS: Vaccination was administered as a 3-dose regimen at day 1, and months 2 and 6. More than 15 000 subjects received ≥1 dose of 9vHPV vaccine. In 2 of the studies, >7000 control subjects received ≥1 dose of quadrivalent HPV (qHPV) vaccine. Serious and nonserious adverse events (AEs) and new medical conditions were recorded throughout the study. Subjects testing positive for pregnancy at day 1 were not vaccinated; those who became pregnant after day 1 were discontinued from further vaccination until resolution of the pregnancy. Pregnancies detected after study start (n = 2950) were followed to outcome. RESULTS: The most common AEs (≥5{\%}) experienced by 9vHPV vaccine recipients were injection-site AEs (pain, swelling, erythema) and vaccine-related systemic AEs (headache, pyrexia). Injection-site AEs were more common in 9vHPV vaccine than qHPV vaccine recipients; most were mild-to-moderate in intensity. Discontinuations and vaccine-related serious AEs were rare (0.1{\%} and <0.1{\%}, respectively). Seven deaths were reported; none were considered vaccine related. The proportions of pregnancies with adverse outcome were within ranges reported in the general population. CONCLUSIONS: The 9vHPV vaccine was generally well tolerated in subjects aged 9 to 26 years with an AE profile similar to that of the qHPV vaccine; injection-site AEs were more common with 9vHPV vaccine. Its additional coverage and safety profile support widespread 9vHPV vaccination.",
author = "Moreira, {Edson D.} and Block, {Stan L.} and Ferris, {Daron Gale} and Giuliano, {Anna R.} and Iversen, {Ole Erik} and Joura, {Elmar A.} and Pope Kosalaraksa and Andrea Schilling and {Van Damme}, Pierre and Jacob Bornstein and Bosch, {F. Xavier} and Sophie Pils and Jack Cuzick and Garland, {Suzanne M.} and Warner Huh and Kjaer, {Susanne K.} and Hong Qi and Donna Hyatt and Jason Martin and Erin Moeller and Michael Ritter and Martine Baudin and Alain Luxembourg",
year = "2016",
month = "8",
day = "1",
doi = "10.1542/peds.2015-4387",
language = "English (US)",
volume = "138",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - Safety profile of the 9-valent HPV vaccine

T2 - A combined analysis of 7 phase III clinical trials

AU - Moreira, Edson D.

AU - Block, Stan L.

AU - Ferris, Daron Gale

AU - Giuliano, Anna R.

AU - Iversen, Ole Erik

AU - Joura, Elmar A.

AU - Kosalaraksa, Pope

AU - Schilling, Andrea

AU - Van Damme, Pierre

AU - Bornstein, Jacob

AU - Bosch, F. Xavier

AU - Pils, Sophie

AU - Cuzick, Jack

AU - Garland, Suzanne M.

AU - Huh, Warner

AU - Kjaer, Susanne K.

AU - Qi, Hong

AU - Hyatt, Donna

AU - Martin, Jason

AU - Moeller, Erin

AU - Ritter, Michael

AU - Baudin, Martine

AU - Luxembourg, Alain

PY - 2016/8/1

Y1 - 2016/8/1

N2 - OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at entry), 9 to 26 years of age. METHODS: Vaccination was administered as a 3-dose regimen at day 1, and months 2 and 6. More than 15 000 subjects received ≥1 dose of 9vHPV vaccine. In 2 of the studies, >7000 control subjects received ≥1 dose of quadrivalent HPV (qHPV) vaccine. Serious and nonserious adverse events (AEs) and new medical conditions were recorded throughout the study. Subjects testing positive for pregnancy at day 1 were not vaccinated; those who became pregnant after day 1 were discontinued from further vaccination until resolution of the pregnancy. Pregnancies detected after study start (n = 2950) were followed to outcome. RESULTS: The most common AEs (≥5%) experienced by 9vHPV vaccine recipients were injection-site AEs (pain, swelling, erythema) and vaccine-related systemic AEs (headache, pyrexia). Injection-site AEs were more common in 9vHPV vaccine than qHPV vaccine recipients; most were mild-to-moderate in intensity. Discontinuations and vaccine-related serious AEs were rare (0.1% and <0.1%, respectively). Seven deaths were reported; none were considered vaccine related. The proportions of pregnancies with adverse outcome were within ranges reported in the general population. CONCLUSIONS: The 9vHPV vaccine was generally well tolerated in subjects aged 9 to 26 years with an AE profile similar to that of the qHPV vaccine; injection-site AEs were more common with 9vHPV vaccine. Its additional coverage and safety profile support widespread 9vHPV vaccination.

AB - OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at entry), 9 to 26 years of age. METHODS: Vaccination was administered as a 3-dose regimen at day 1, and months 2 and 6. More than 15 000 subjects received ≥1 dose of 9vHPV vaccine. In 2 of the studies, >7000 control subjects received ≥1 dose of quadrivalent HPV (qHPV) vaccine. Serious and nonserious adverse events (AEs) and new medical conditions were recorded throughout the study. Subjects testing positive for pregnancy at day 1 were not vaccinated; those who became pregnant after day 1 were discontinued from further vaccination until resolution of the pregnancy. Pregnancies detected after study start (n = 2950) were followed to outcome. RESULTS: The most common AEs (≥5%) experienced by 9vHPV vaccine recipients were injection-site AEs (pain, swelling, erythema) and vaccine-related systemic AEs (headache, pyrexia). Injection-site AEs were more common in 9vHPV vaccine than qHPV vaccine recipients; most were mild-to-moderate in intensity. Discontinuations and vaccine-related serious AEs were rare (0.1% and <0.1%, respectively). Seven deaths were reported; none were considered vaccine related. The proportions of pregnancies with adverse outcome were within ranges reported in the general population. CONCLUSIONS: The 9vHPV vaccine was generally well tolerated in subjects aged 9 to 26 years with an AE profile similar to that of the qHPV vaccine; injection-site AEs were more common with 9vHPV vaccine. Its additional coverage and safety profile support widespread 9vHPV vaccination.

UR - http://www.scopus.com/inward/record.url?scp=84982855434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982855434&partnerID=8YFLogxK

U2 - 10.1542/peds.2015-4387

DO - 10.1542/peds.2015-4387

M3 - Article

VL - 138

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

M1 - e20154387

ER -